All News

Carlos Silva Rondon, MD, of Moffitt Cancer Center discussed factors guiding selection between CAR T therapy or bispecific antibodies in follicular lymphoma.

Kathryn Eckert, DO, discussed her role of bridging surgery and radiology teams as breast biopsy needle shortages continue nationwide.

This cross-sectional study evaluated the genetic landscape of a cohort of patients with metastatic prostate cancer who were treated at a referral center in Mexico City, Mexico.

Megan Melody, MD, says it could be “years” before data clarify how to sequence bispecific antibodies and CAR T-cell therapy.

Findings from the global, single-arm phase 1/2 ARROS-1 trial in patients with advanced or metastatic ROS1-positive NSCLC support the regulatory decision.

Fast track designation supports pelareorep's development for anal cancer that progresses after first-line checkpoint inhibitor-based therapy.

Investigators will evaluate carotuximab plus radium-223 to overcome treatment resistance in metastatic CRPC with bone metastases.

Updated phase 3 HARMONi trial data show ivonescimab plus chemotherapy improves overall survival in Western and Asian EGFR-mutant NSCLC groups.

Exploratory data showed that serplulimab maintenance or continuation beyond initial progression may yield incremental survival benefits in ES-SCLC.

Two hematologic oncologists debated the clinical trade-offs of CAR T-cell therapy vs bispecific antibodies in relapsed/refractory follicular lymphoma.

Megan Melody, MD, says acute CAR T-cell toxicities are well managed, but delayed neurotoxicity remains a challenge.

A 10-year analysis of 3477 patients found low prostate cancer–specific mortality with focal high-intensity focused ultrasound or cryotherapy for nonmetastatic disease.

Kathryn Eckert, DO, described how her breast surgery practice and imaging partners responded on day 1 of the Hologic Brevera needle recall.

A peptide vaccine targeting KRAS variants was safe and produced durable T-cell responses in individuals with hereditary predisposition for pancreatic ductal adenocarcinoma.

Courtney D. DiNardo, MD, MSCE; and Michael R. Savona, MD, weigh whether ASCERTAIN-V data make oral HMA therapy the frontline default in AML.

Patients with a multiple myeloma relapse within 36 months of up-front quadruplet therapy and transplantation should be prioritized for immunotherapy, said Gayathri Ravi, MD.

Traditional acupuncture plus auricular acupressure improved overall quality of life among patients with HNSCC undergoing radiotherapy.

A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.

The approval of Orca-T represents a “big advance” that must be studied further, according to Wendy Stock, MD.

A pharmacist explored how recent NCCN guideline updates leverage ctDNA MRD testing to guide adjuvant immunotherapy and improve EFS in bladder cancer.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, explained how an all-oral AML regimen impacts infusion center logistics and patient visits.

A pharmacist discussed the operational hurdles, payer coverage rates, and lack of standardized surveillance protocols for bladder cancer ctDNA testing.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, discussed how fast oral DEC-C plus venetoclax may replace IV HMA regimens in AML.

In 50,845 SEER patients aged ≥70 years with stage I ER-positive breast cancer after BCS, radiation omission was not associated with inferior BCSS (aHR, 0.95; 95% CI, 0.87-1.04), though radiation conferred modest OS benefit, supporting selective de-escalation in older patients.

Data from the phase 3 ENDURANCE trial challenge the assumption that a longer duration of therapy is likely to better multiple myeloma care.

Adjuvant atezolizumab nearly doubled disease-free survival in patients with ctDNA-positive muscle-invasive bladder cancer in the phase 3 IMvigor011 trial.

Sara Hurvitz, MD, FACP, explained how to prevent and manage stomatitis in patients with breast cancer receiving the newly approved gedatolisib.

Experts discuss sequencing HER2-, FGFR3-, and nectin-4–directed therapies after enfortumab vedotin and pembrolizumab in urothelial cancer.

In a prospective pilot of 74 patients enriched for under-represented risk factors, 15-fraction breast/chest wall RT with SIB yielded 10-year LRFS of 93.1%, DMFS of 94.2%, and OS of 89.2%, with no grade 3 brachial plexopathy or significant lymphedema, supporting condensed SIB use in routine practice.

In 536,783 NCDB breast RT courses from 2020 to 2023, 5-fraction RT rose from 4.3% to 17.4% overall, with uptake significantly lower among uninsured patients (6.9%), Black patients (9.4% vs 12.2% White), and mid-size metro areas, revealing persistent access disparities.